Hong Kong
· Delayed Price · Currency is HKD Livzon Pharmaceutical Group Statistics
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of HKD 33.01 billion. The enterprise value is 26.64 billion.
| Market Cap | 33.01B |
| Enterprise Value | 26.64B |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | Jul 8, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.74% |
| Shares Change (QoQ) | +1.60% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 482.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.46, with an EV/FCF ratio of 9.00.
| EV / Earnings | 11.88 |
| EV / Sales | 2.09 |
| EV / EBITDA | 7.46 |
| EV / EBIT | 10.53 |
| EV / FCF | 9.00 |
Financial Position
The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.27.
| Current Ratio | 1.84 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 1.23 |
| Debt / FCF | 1.53 |
| Interest Coverage | 24.59 |
Financial Efficiency
Return on equity (ROE) is 15.09% and return on invested capital (ROIC) is 7.84%.
| Return on Equity (ROE) | 15.09% |
| Return on Assets (ROA) | 5.91% |
| Return on Capital (ROIC) | 7.84% |
| Revenue Per Employee | 1.47M |
| Profits Per Employee | 251,064 |
| Employee Count | 8,933 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +11.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +11.09% |
| 50-Day Moving Average | 27.15 |
| 200-Day Moving Average | 26.26 |
| Relative Strength Index (RSI) | 47.23 |
| Average Volume (20 Days) | 699,423 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of HKD 13.13 billion and earned 2.24 billion in profits. Earnings per share was 2.42.
| Revenue | 13.13B |
| Gross Profit | 8.27B |
| Operating Income | 2.61B |
| Pretax Income | 3.01B |
| Net Income | 2.24B |
| EBITDA | 3.65B |
| EBIT | 2.61B |
| Earnings Per Share (EPS) | 2.42 |
Balance Sheet
The company has 11.97 billion in cash and 4.54 billion in debt, giving a net cash position of 7.43 billion.
| Cash & Cash Equivalents | 11.97B |
| Total Debt | 4.54B |
| Net Cash | 7.43B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 16.54B |
| Book Value Per Share | 17.11 |
| Working Capital | 8.42B |
Cash Flow
In the last 12 months, operating cash flow was 3.70 billion and capital expenditures -743.27 million, giving a free cash flow of 2.96 billion.
| Operating Cash Flow | 3.70B |
| Capital Expenditures | -743.27M |
| Free Cash Flow | 2.96B |
| FCF Per Share | n/a |
Margins
Gross margin is 62.94%, with operating and profit margins of 19.84% and 17.08%.
| Gross Margin | 62.94% |
| Operating Margin | 19.84% |
| Pretax Margin | 22.90% |
| Profit Margin | 17.08% |
| EBITDA Margin | 27.83% |
| EBIT Margin | 19.84% |
| FCF Margin | 22.55% |
Dividends & Yields
Livzon Pharmaceutical Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | -15.01% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 67.66% |
| Buyback Yield | 0.74% |
| Shareholder Yield | 0.74% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 3, 2019. It was a forward split with a ratio of 1.3.
| Last Split Date | Jul 3, 2019 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
Livzon Pharmaceutical Group has an Altman Z-Score of 3.62.
| Altman Z-Score | 3.62 |
| Piotroski F-Score | n/a |